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Autism spectrum disorder (ASD) is an umbrella term for a heterogeneous group of
developmental disorders that present with persistent deficits in social communication/interaction
and repetitive/restricted patterns of behavior, interests, or activities that cannot be better explained
by intellectual disability or global developmental delay (DSM-5 APA, 2013). The recent estimate for
ASD in 8-year old children in the United States is one in 68 (Baio and Autism and Developmental
Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators, 2014). Although
a genetic cause can be identified in 20–25% cases (reviewed in Miles, 2011), the etiology of ASD
still remains largely unclear. Several possible factors have been investigated to explain the etiology
of ASD, i.e., immune dysregulation and inflammation, oxidative stress, mitochondrial dysfunction,
and environmental factors (Rossignol and Frye, 2012).
Children with ASD have a variety of psychiatric, neurological, nutritional/metabolic, and other
medical conditions (Venkat et al., 2012). One of the most common ASD comorbidities is a gut
disorder, affecting 9–90% of ASD patients depending on the definitions and the groups studied
(Buie et al., 2010). In comparison with typically developing children, general gastrointestinal (GI)
symptoms are over five times more common in children with ASD; abdominal pain is reported
more than twice as much and both constipation and diarrhea have four times higher incidence
(McElhanon et al., 2014). Although gut disorders are not exclusive for ASD (Chaidez et al.,
2014), there is a strong correlation of GI disturbances with autism severity (Adams et al., 2011).
Abdominal pain could certainly worsen the behavior, especially in ASD patients that cannot express
their discomfort due to speech impairment. Furthermore, recent findings point out to a more
substantial association between the brain and the gut (Mayer et al., 2014).
Genetic mutations that cause impairment of the central nervous system (CNS) could directly
affect the enteric nervous system (ENS), a nervous tissue within the gut wall often called “the
second brain” due to its size, structure, complexity, and autonomic regulation of gut functions,
such as bowel motility, secretion/absorption and local blood flow (Furness, 2006, 2012). For
instance, a recent study reported reduced upper GI and distal colonic transit velocities in
mice heterozygous for the deletion of Transcription factor 4 (TCF4) (Grubišic´ et al., 2015),
emulating symptoms, i.e., gastroesophageal reflux and constipation, of patients with the Pitt-
Hopkins Syndrome (PTHS) (Whalen et al., 2012), a very rare ASD (Sweatt, 2013), caused
by the haplo-insufficiency of the TCF4 gene (Amiel et al., 2007; Brockschmidt et al., 2007;
Zweier et al., 2007). Due to no obvious malformation of the gut in these animals (Grubišic´
et al., 2015) and the role of the basic helix-loop-helix transcription factors in neural crest
development (Nelms and Labosky, 2010), we hypothesized that the reduced bowel motility
in the above mouse model of PTHS was caused by the ENS dysfunction. Additionally, gut
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microbiota and GI barrier permeability were implicated as
important etiological factors of ASD (Hsiao et al., 2013).
Microbiota are locally important for maintaining the GI
epithelial barrier (Kabouridis et al., 2015), while bacterial
metabolites reaching the CNS can cause neuroinflammation and
behavioral changes that resemble ASD (MacFabe et al., 2011).
These findings indicate that GI disturbances, besides having an
impact on the quality of life, can also contribute to the severity
of neurological and psychiatric symptoms in ASD patients.
Therefore, more research is needed to pinpoint the role of the
second brain in ASD.
In recent years, enteric glial cells (EGCs), traditionally
considered as only supportive cells of the ENS, are emerging
as local GI regulators. They are strategically located at the
interface between the neurons and other non-neuronal cells in
the gut, such as enterocytes or immune cells, and participate in
the regulation of gut motility, intestinal epithelial barrier, and
inflammatory processes (reviewed in Gulbransen and Sharkey,
2012; Neunlist et al., 2014; Coelho-Aguiar et al., 2015; Sharkey,
2015). Ablation and functional inhibition of EGCs lead to severe
GI inflammation (Bush et al., 1998) and decreased gut motility
(Nasser et al., 2006), respectively. Indeed, EGCs respond to
neuronal activity during bowel movement (Broadhead et al.,
2012) and actively participate in the regulation of intestinal
transit (McClain et al., 2014). EGCs also affect enterocytes
and epithelial permeability by releasing factors such as S-
nitrosoglutathione (GSNO) (Savidge et al., 2007), glial-derived
neurotrophic factor (Zhang et al., 2010), 15-deoxy-112,14-
prostaglandin J2 (Bach-Ngohou et al., 2010), and pro-epidermal
growth factor (Van Landeghem et al., 2011). This functional
connection between the ENS and intestinal epithelium has
been termed the neuronal-glial-epithelial unit to acknowledge
its importance in GI health and disease (Neunlist et al.,
2013). Finally, EGCs directly regulate inflammatory processes
using immunological signaling pathways activated via, e.g., the
major histocompatibility complex class II (Geboes et al., 1992),
interleukin 1 receptor (Stoffels et al., 2014), chemokine CCL20
(Fagbemi et al., 2013), or toll-like receptors 2 and 4 (Brun et al.,
2013; Esposito et al., 2014). Since ASD patients have increased
epithelial leakiness and inflammation in the gut, as well as
impaired bowel motility, EGCs could play an important role in
ASD etiology and/or progression.
EGCsmorphologically and functionally resemble astrocytes of
the CNS (reviewed in Gulbransen, 2014) and altered expression
of astrocytic markers was found in brains of autistic patients
(Fatemi et al., 2008). One particularly interesting finding is the
increased expression of connexin 43 (Cx43) in the superior
frontal cortex, a part of the brain responsible for higher
social, cognitive and emotional functions (Fatemi et al., 2008),
suggesting that selective astrocytic network dysregulation plays
a role in characteristic symptoms of autism. Additional work
is needed to determine whether subcellular localization of
Cx43 and functional cell-to-cell coupling via Cx43 are also
affected. Nonetheless, the increased expression of Cx43 could
be compensatory due to the protein removal from the cell
surface. Here, internalization of Cx43 is quite possible because
brain inflammation was recently recognized as a hallmark of
autism (Gupta et al., 2014) and, concurrently, CNS infection
and inflammation are known to cause Cx43 internalization in
astrocytes (reviewed in Castellano and Eugenin, 2014).
Since the expression of Cx43 has been recently confirmed
in EGCs (McClain et al., 2014), here, we speculate that
changed expression of Cx43 in EGCs could affect the above
mentioned ASD-related GI pathophysiology, i.e., motility,
epithelial leakiness and inflammation. To corroborate our theory,
we use findings from studies conducted on EGCs, as well as on
astroglia. However, it is important to keep in mind that astrocytes
and EGCs are two distinct cell types due to different origin and
molecular composition (reviewed in Gulbransen, 2014).
Recent study showed the role of EGCs’ Cx43 hemichannels
in the regulation of the GI motility (McClain et al., 2014).
Selective inhibition of Cx43 hemichannels reduced the Ca2+
wave propagation between the EGCs in situ and inducible knock-
out of Cx43 encoding gene selectively from EGCs reduced the
colonic transit in vivo. This genetic manipulation also reduced
contractility of ex vivo colonic muscle strips. It is therefore
tempting to speculate that constipation and reduced GI motility
in ASD patients could partly come from the reduced Cx43
expression/function at the plasma membrane of EGCs. One
possibility is a change in Cx43 transcription. For instance, some
monogenetic ASDs that are caused by the mutations in genes
encoding epigenetic or transcription factors, e.g., methyl CpG
binding protein 2 (MeCP2) in Rett Syndrome (Yasui et al., 2013)
or the above mentioned TCF4 in PTHS, respectively, could affect
transcriptional machinery required for adequate expression of
Cx43 in EGCs (reviewed in Oyamada et al., 2013) and, in turn,
affect GI motility in patients with ASD. The other scenario could
be the secondary effect of intestinal inflammation, a common GI
feature in autistic patients, affecting Cx43 subcellular localization
and function in EGCs.
Concurrently, Cx43 on EGCs is taking part in the
inflammatory process. Neuronal loss is one of the characteristics
of intestinal inflammation and is driven by the activation of
neuronal purinergic receptor (Gulbransen et al., 2012). Recently,
inhibition or genetic ablation of EGCs’ Cx43 prevented the
inflammation induced neuronal death (Brown et al., 2015).
This is interesting because ATP released from EGCs via Cx43
hemichannels is involved in both inflammation and motility
(McClain et al., 2014), as mentioned above. Additionally, direct
cell-to-cell contact via Cx43 gap junctions can modulate immune
responses (Westphalen et al., 2014), so EGCs might regulate
immune cells activation in a similar fashion and further regulate
the inflammatory process.
Animals with ablated Cx43 in EGCs also exhibited an
increased fluid content in stools, indicating disabled water
reabsorption/secretion (McClain et al., 2014). This could occur
via altered EGC-enteroendocrine cell interactions (Bohorquez
et al., 2014). Alternatively, the finding may imply a role of
EGCs’ Cx43 in regulation of the gut epithelium barrier, as EGCs
are active players in the neuronal-glial-epithelial unit and have
protective effects on enterocytes. A co-culture study showed that
EGCs increase the transcription of enterocyte genes involved in
cell-to-cell and cell-to-matrix adhesion, and also demonstrated
an increase in cell adhesion (Van Landeghem et al., 2009).
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FIGURE 1 | Is Cx43 on enteric glia involved in autism spectrum
disorder (ASD)? (A) Enteric glial cells (EGCs) interact with enteric neurons
within the enteric nervous system and other cells in the gut wall, such as
enterocytes, vasculature endothelial and immune cells, regulating
gastrointestinal (GI) motility, as well as epithelial/endothelial barriers and
inflammation in the intestine; these interactions could happen through
cell-to-cell coupling via Cx43 gap junctions or factors released through Cx43
hemichannels. (B) Possible roles for EGCs’ Cx43 in the vicious cycle of GI
disturbances in ASD. Regardless of the etiology, e.g., gene mutation or
environmental factors, ASD often leads to similar GI clinical manifestations,
i.e., reduced motility and inflammation, because pathophysiological
processes are interconnected. Cx43 on enteric glia could be involved in all
the processes and contribute to the overall clinical picture. Question marks
(?) indicate untested interactions/processes. Arrows indicate relationships
between the processes (dashed lines indicate processes not directly linked
to EGCs’ Cx43).
Some of the glia-derived factors, e.g., prostaglandins, could be
released through the Cx43 hemichannels (Cherian et al., 2005).
The other effects could come from the direct cell-to-cell contact.
EGCs are in proximity of enterocytes (Liu et al., 2013) and
both the cell types express Cx43 (Leaphart et al., 2007), so
homotypic Cx43 gap junctions could couple these two cell types.
Cx43 is known to regulate cell-to-cell contact gene expression
(Lecanda et al., 1998), perhaps by affecting intercellular
diffusion of secondary messengers and cytosolic Ca2+oscillations
that can consequently regulate gene transcription (Dolmetsch
et al., 1997; Sassone-Corsi, 1998). Additionally, gap junction
coupling could also affect the membrane potential, due to the
potential difference between the EGCs and enterocytes, i.e.,
about −55mV and −25mV (Cremaschi et al., 1982; Hanani
et al., 2000), respectively, that could consequently also affect
gene expression and cell physiology. Indeed, membrane potential
of differentiating enterocytes becomes more positive exclusively
due to their migration away from the crypt-villus junction
(Cremaschi et al., 1984), where there is higher probability to
interact with EGCs (Liu et al., 2013).
EGCs are also in proximity of capillaries within the gut wall
(Fu et al., 2013), so they might have a role in the regulation
of vascular permeability, resembling astrocytes that take part in
the formation of the blood-brain-barrier (BBB). Indeed, EGCs
have the intrinsic ability to participate in BBB formation after
their transplantation into the spinal cord (Jiang et al., 2005). In
the CNS, astrocytic specialized processes, termed endfeet, highly
express Cx43 and wrap blood vessels (Simard et al., 2003). The
loss of Cx43 causes astrocyte endfeet edema and weakens the BBB
(Ezan et al., 2012). If similar mechanism takes place in the gut,
the loss of Cx43 from EGCs would increase the permeability of
the intestinal vasculature providing a link for the gut-brain axis
in ASD, perhaps by contributing to brain inflammation (Gupta
et al., 2014), and enhancing the CNS-related symptoms in autistic
patients.
In summary, we presented a hypothetical link between the
Cx43 of EGCs and GI related symptoms in patients with autism
(Figure 1). EGCs interact with multiple cell types in the gut wall,
perhaps by releasing factors via Cx43 hemichannels and/or cell-
to-cell coupling via Cx43 gap junctions (Figure 1A). The changes
in Cx43 expression, subcellular localization and function have
the potential to directly affect motility, epithelial permeability,
and inflammatory processes of the gut. These processes are
connected in the feed-forward loop forming a vicious cycle
(Figure 1B). Cx43 in EGCs could also affect the permeability
of the intestinal vasculature and consequently contribute to the
severity of ASD in the brain. At this juncture it is speculative
whether GI manifestations are simply part of the ASD clinical
picture or insult to the gut precedes autistic behavior. Since
ASD is so diverse, both the scenarios may play out, but in
different cases. EGCs and Cx43 could have a role in either of
the scenarios and therefore deserve additional attention. This
could eventually enable us to ameliorate, if not prevent, the GI
disturbances and some of the CNS-related symptoms in patients
with ASD.
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